摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

potassium 1-(1H-pyrrol-2-ylmethyl)-1H-pyrazol-4-carboxylate | 1449320-92-6

中文名称
——
中文别名
——
英文名称
potassium 1-(1H-pyrrol-2-ylmethyl)-1H-pyrazol-4-carboxylate
英文别名
potassium 1-(1H-pyrrol-2-ylmethyl)-1H-pyrazole-4-carboxylate;Potassium 1-(1H-pyrrol-2-ylmethyl)-1H-pyrazole-4-carboxylate;potassium;1-(1H-pyrrol-2-ylmethyl)pyrazole-4-carboxylate
potassium 1-(1H-pyrrol-2-ylmethyl)-1H-pyrazol-4-carboxylate化学式
CAS
1449320-92-6
化学式
C9H8N3O2*K
mdl
——
分子量
229.28
InChiKey
GSXCRDCXKUWXJK-UHFFFAOYSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -3.37
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.11
  • 拓扑面积:
    73.7
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE 1H-PYRROLO[2,3-B]PYRIDINE ET LEUR UTILISATION COMME INHIBITEURS DE KINASES
    申请人:VERNALIS R & D LTD
    公开号:WO2013114113A1
    公开(公告)日:2013-08-08
    The inventions relates to compounds of (I) and therapeutic uses thereof : (I) The terms Z, Y, and R1 are as defined in the claims.
    本发明涉及式(I)化合物的化合物及其治疗用途:(I) 其中Z、Y和R1的定义如权利要求中所述。
  • NOVEL TRIAZINE DERIVATIVE
    申请人:CARNA BIOSCIENCES, INC.
    公开号:US20150011751A1
    公开(公告)日:2015-01-08
    To provide a novel triazine derivative represented by the following formula (I): A triazine derivative represented by the following formula (I): wherein R 1 represents a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, a substituted or unsubstituted heterocyclic fused ring, or a substituted or unsubstituted alkynyl group, R 2 represents a hydrogen atom, a halogen atom, a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted alkoxy group, R 3 represents a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, or a substituted or unsubstituted heterocyclic fused ring, R 4 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, or a halogen atom, and R 5 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, or R 1 and R 5 may be combined to form a saturated or unsaturated 5- to 6-membered ring, thereby forming a multiply fused ring, or a pharmaceutically acceptable salt thereof.
    提供以下式子(I)所代表的新型三嗪衍生物: 式子(I)中,R1代表取代或未取代的芳基基团、取代或未取代的杂环环、取代或未取代的杂环融合环或取代或未取代的炔基基团; R2代表氢原子、卤素原子、取代或未取代的较低烷基基团或取代或未取代的烷氧基; R3代表取代或未取代的芳基基团、取代或未取代的杂环环或取代或未取代的杂环融合环; R4代表氢原子、取代或未取代的较低烷基基团、取代或未取代的烷氧基、取代或未取代的基基团或卤素原子; R5代表氢原子、取代或未取代的较低烷基基团或R1和R5可以结合形成饱和或不饱和的5-6元环,从而形成多重融合环;或其药学上可接受的盐。
  • 1H-pyrrolo[2,3-B] pyridine derivatives and their use as kinase inhibitors
    申请人:VERNALIS (R&D) LIMITED
    公开号:US10000481B2
    公开(公告)日:2018-06-19
    The inventions relates to compounds of (I) and therapeutic uses thereof: (I) The terms Z, Y, and R1 are as defined in the claims.
    本发明涉及 (I) 的化合物及其治疗用途: (I) 术语 Z、Y 和 R1 如权利要求中所定义。
  • 1H-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors
    申请人:Vernalis (R&D) Limited
    公开号:US10889582B2
    公开(公告)日:2021-01-12
    The inventions relates to compounds of (I) and therapeutic uses thereof: (I) The terms Z, Y, and R1 are as defined in the claims.
    本发明涉及 (I) 的化合物及其治疗用途: (I) 术语 Z、Y 和 R1 如权利要求中所定义。
  • 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS
    申请人:Vernalis (R&D) Limited
    公开号:EP2809670A1
    公开(公告)日:2014-12-10
查看更多